Has Mark Schinsky, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,077,969 in general payments to Mark Schinsky, MD across 907 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Schinsky, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Schinsky, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Schinsky, MD

Orthopaedic Surgery · Des Plaines, ILNPI 1639125842

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 75.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $275,511 and has fallen 87.4% since, to $34,675 in 2025. Among orthopaedic surgery clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,077,969in general payments, 2019–2025

Across 907 payments — averaging $1188.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Smith+Nephew$811K
Limacorporate S.p.a.$87K
Exactech, Inc.$74K
Techmah Medical, LLC$60K
Lima USA, Inc.$24K
Microport Navibot International LLC$7K
plus $15K from 14 others

$256,618in research payments, 2019–2025

Across 29 payments — averaging $8848.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Smith+Nephew$178K
Limacorporate S.p.a.$78K

What the payments were for

Royalty or licence$1,3740%
Consulting fees$415,45539%
Speaking & faculty fees$486,69545%
Travel & lodging$151,53514%
Food & beverage$22,8972%
Education$140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Smith+Nephew	639	$811,445
Limacorporate S.p.a.	34	$86,508
Exactech, Inc.	62	$73,982
Techmah Medical, LLC	64	$59,526
Lima USA, Inc.	31	$24,452
Microport Navibot International LLC	7	$6,949
Medical Device Business Services, Inc.	6	$6,682
Encore Medical, LP	7	$2,467
Stryker	16	$1,640
Microport Orthopedics Inc	12	$1,213
Conformis, Inc.	3	$971
Zimmer Biomet	8	$963
Johnson & Johnson	8	$487
Amgen	3	$324
Next Science LLC	2	$169
Medacta USA, Inc.	1	$68
Pacira Pharmaceuticals Incorporated	1	$61
Advita Ortho, LLC	1	$23
Electronic Waveform Lab, Inc.	1	$22
Heraeus Medical, LLC.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,077,969 in reported general payments places this provider in the 95th percentile of 844 orthopaedic surgery providers in Illinois.

See all orthopaedic surgery providers in Illinois →

Medicare billing

Part B allowed, 2024

$194,271

Medicare patients

271

Services billed

2,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	14	$127
Meloxicam	12	$15
Amoxicillin	12	$10

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Des Plaines

Peter BonuttiEffingham$24.3M
Steven HaddadGlenview$12.6M
Aaron RosenbergChicago$12.4M
Treg BrownHerrin$6.6M
Wayne GoldsteinMorton Grove$4.9M
Steven ChudikWestmont$4.1M
Matthew SquireAurora$2.9M
David ManningBurr Ridge$2.3M
Ritesh ShahMorton Grove$2.3M
Anish KadakiaChicago$2.1M

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →